Die Opko Health Inc. (OPK) ist ein diversifiziertes biopharmazeutisches und Diagnostikunternehmen. Der Fokus liegt auf der Entwicklung und Kommerzialisierung von…
OPK earnings call for the period ending September 30, 2024.…
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual…
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Healths laboratory testing…
OPK earnings call for the period ending June 30, 2024.…
…
Despite OPKO Healths (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.…
OPK earnings call for the period ending March 31, 2024.…
…
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
NEW YORK, April 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory…
NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.…
Opko Health CEO Phillip Frost buys $444,300 in company stock…
Earnings call: OPKO Health reports mixed Q4 results…
Stocks Analysis by MarketBeat.com (Thomas Hughes) covering: Opko Health Inc, Southland Holdings Inc. Read MarketBeat.com (Thomas Hughes)s latest article on…
OPK earnings call for the period ending December 31, 2023.…
…
Opko Health earnings beat by $0.01, revenue topped estimates…
…
Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds…
OPK earnings call for the period ending September 30, 2023.…
…
Despite OPKO Healths (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.…
MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE®…
MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on…
…
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a…
Frost, Phillip Md Et Al - Vorstand - Tag der Transaktion: 2023-08-17...…
Frost, Phillip Md Et Al - Vorstand - Tag der Transaktion: 2023-08-14...…
Frost, Phillip Md Et Al - Vorstand - Tag der Transaktion: 2023-08-07...…
Despite OPKO Healths (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances....…
OPK earnings call for the period ending June 30, 2023....…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
The FDA approved a growth therapy the company was collaborating on with Pfizer....…
NEW YORK CITY (dpa-AFX) - Biopharmaceutical major Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced on Wednesday that the…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
OPKO Health (OPK) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Nabel, Gary J. - Vorstand - Tag der Transaktion: 2023-05-05...…
Despite OPKO Healths (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances....…
OPK earnings call for the period ending March 31, 2023....…
OPKO Health (OPK) delivered earnings and revenue surprises of 71.43% and 26.76%, respectively, for the quarter ended March 2023. Do…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…